AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05757765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STOPP-START deprescribing approach (SSA)
Description: The usual care in the geriatric medicine in the Netherlands consisting of a medication review based on the STOPP-START criteria. These criteria have been combined in a protocol that describes when certain medication(groups) must be continued or discontinued for specific patient characteristics.
Study NCT06331247 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General dietary advice
Description: General dietary advice according to the Chinese Dietary Guidelines 2022.
Study NCT06331247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General dietary advice
Description: General dietary advice according to the Chinese Dietary Guidelines 2022.
Study NCT06331247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Localized MIND diet intervention
Description: The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
Study NCT05999760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: masticatory performance(questionnaire)
Description: Evaluation of masticatory performance of Versacryle and CAD/CAM partial dentures by questionnaire on day one, on first month, and on the second month of prosthesis delivery.
Study NCT06331247 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine medical care
Description: Routine medical care and follow-ups.
Study NCT06331247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine medical care
Description: Routine medical care and follow-ups.
Study NCT04847323 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V-bend Bonded Retainer
Description: Traditional stainless steel retainer commonly bonded in the anterior teeth of the mandibular arch to maintain their alignment after orthodontic treatment.
Study NCT04847323 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum-formed Retainer
Description: Removable retainers made of plastic and derivatives. Currently gaining popularity due to the increased use of esthetic aligners. These clear retainers have the objective to maintain stable the results obtained after orthodontic treatment. They cover all the surfaces of the teeth up to the first or second molars.
Study NCT05533060 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: patients in the groups are treated surgically and brain tissue, CSF, and blood samples, as well as clinical data, neuroimaging data are collected
Study NCT06036446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Description: Transvaginal cervical cerclage placed between 24 0/7 - 26 6/7 weeks of gestation.
Study NCT05675735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-Level Multidimensional Intervention
Description: The proximal goal of the intervention will be to increase OTP uptake of flexible THD. The intervention addresses facilitators and barriers to THD practices as identified by existing studies as well as those found during the first phase of the current project. The intervention will be designed to address the information gaps, training needs, and beliefs of individuals across the organizations.
Study NCT06036446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Suppository Progesterone
Description: Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
Study NCT06036446 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vaginal Suppository Progesterone
Description: Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
Study NCT04248959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Description: Multimodal Prehabilitation~* Aerobic exercise~  * Home-based, high-intensity interval training (HIIT), 2 days/week~ * Home-based, moderate-intensity continuous training (MICT), 2-3 days/week~* Resistance exercise~  * Home-based, moderate-intensity resistance training, 2-3 d/wk, all major muscle groups (working around tumour-related deficits), 8-10 exercises, 12-15 repetitions, resistance bands and body weight based~* Nutrition~  * Protein intake 1.2-1.5 g/kg body weight/day in compliance with European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines~* Stress management~  * Daily mindfulness practice, 20 min/session, guided by audio file created at Mount Sinai Hospital
Study NCT04903821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3427080
Description: Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8
Study NCT05427877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heating device (Heatwave Technology)
Description: Heating devices will be applied to the trunk and extremities of the body during the first study visit. During each heating cycle, the temperature will increase quickly from room temperature to a high of 45C and then cycle back down. Each heating cycle is 30 minutes with a 3 minute cool down period where no heat is applied. The maximum temperature used in this study is 45 degrees C (113 degrees F). There will be a total of 3 heating cycles at the visit.
Study NCT05503667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furmonertinib
Description: Furmonertinib 80 mg/day for 16 weeks
Study NCT05503667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib 80 mg/day for 16 weeks
Study NCT05503667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 400 mg/4 weeks i.v. for 4 times
Study NCT05855161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound therapy
Description: Participants will receive exercise-based training on a trampoline
Study NCT05855161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises on a stable surface
Description: Participants will receive exercise-based training on a stable surface
Study NCT04705844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)
Study NCT04705844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)
Study NCT05146102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ethics communication in group, in line with the one to five-step method
Description: Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They will continue by going through an education program for facilitating ethics communication in group, in line with the one to five-step method~The education program has a theoretical and practical approach, which includes the theoretical base of the ethical communication in groups and practicing the one to five method Thereafter, each ethical representative will facilitate interprofessional sessions at a clinical ward, once a month, for six months at their workplace. Gathering meetings for feedback will be offered for the ethical representatives once a month.
Study NCT05981989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural electrical stimulation (EES)
Description: Subjects will undergo a surgical procedure to implant a system that provides epidural electrical stimulation (EES) of the cervical spinal cord. After surgery, subjects will undergo a structured physical rehabilitation program and electrical stimulation.
Study NCT04808557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biorepair Total Protection
Description: Volunteers will use Biorepair Total Protection for home oral hygiene for the following 30 days from the bonding procedure.
Study NCT04808557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensodyne Repair & Protect
Description: Volunteers will use Sensodyne Repair \& Protect for home oral hygiene for the following 30 days from the bonding procedure.
Study NCT05633745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEU-723
Description: Oral Doses
Study NCT05633745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Doses
Study NCT05309876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle tool
Description: Regular use of the digital Lifestyle tool
Study NCT05055245 — intervention group
Intervention type: OTHER
Intervention: cycles
Description: Patients are grouped according to the number of IVF/ICSI cycles.
Study NCT05337033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPL-001
Description: CBD50 plus is a medical cannabis oil with flavouring agent produced under Good Manufacturing Practice by MediPharm Labs and purchased for this study. Each ml of oil contains 2 mg/ml of delta-9-THC and 50 mg/ml of CBD.~Participants will receive escalating doses from 0.2-0.4 mg/kg/day of CBD to 0.8-1 mg/kg of CBD per day for four months, with dose increases monthly in 0.2mg/kg increments. Participants will following a weekly weaning protocol.
Study NCT05606003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Level Multi-Component Intervention (MLI)
Description: The strategic components of our multi-level, multi-component intervention (MLI) include: 1. Building testing access for vulnerable populations, 2) Community Health Worker (CHW)-delivered navigation to SARSCoV- 2 testing and access and reinforce risk mitigation recommendations, 3) 2-1-1 helpline-referrals and navigation to FDA approved SARSCoV- 2 testing (and self sampling once approved) and risk mitigation education, and 4) social marketing and small media campaign to provide geo-targeted messages promoting testing and COVID risk mitigation behaviors. We selected these components because of their evidence base, their current use by partners in response to COVID 19, and confidence that they can be adapted through a community engaged process as described.
Study NCT05606003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Just-In-Time Adaptive Intervention (Community JITAI)
Description: This intervention includes the same MLI components described above, with an added JITAI approach. Community and stakeholder partners will use real-time data related to testing and other relevant information generated by the Epidemiologic Surveillance and Analysis team (ESA) in Aim 1, as well as other information based on their community and stakeholder experience and tacit knowledge about factors influencing testing determinants, to adapt intervention activities as needed to optimize access to testing.
Study NCT05397704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain pulse oximeter
Description: brain oxygen monitoring during hypoxia
Study NCT06436664 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tooth brushing
Description: Firstly, the toothbrush must be positioned at a 45° angle to the gingival margin. Secondly, the brush should be moved back and forth in small horizontal jerks. Thirdly, with a vertical movement, the brush should be moved in the occlusal direction, i.e. upwards in the lower jaw and downwards in the upper jaw to remove debris.
Study NCT06436664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tooth brushing
Description: Firstly, the toothbrush must be positioned at a 45° angle to the gingival margin. Secondly, the brush should be moved back and forth in small horizontal jerks. Thirdly, with a vertical movement, the brush should be moved in the occlusal direction, i.e. upwards in the lower jaw and downwards in the upper jaw to remove debris.
Study NCT05491460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5 MG Tab
Description: oral intake
Study NCT05491460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran 150 MG Tab
Description: oral intake
Study NCT05491460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban 60Mg Tab
Description: oral intake
Study NCT05491460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 20 MG Tab
Description: oral intake
Study NCT05935384 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant360
Description: Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.
Study NCT04473235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Literacy training
Description: Teaching adults how to read and write using the analytical and phonemic method
Study NCT04473235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Literacy training
Description: Attending classes in geography, history, sciences, without receiving the specific training in literacy
Study NCT06165458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide gel + violet LED
Description: Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by violet LED
Study NCT06165458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide gel + blue LED
Description: Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by blue LED
Study NCT06165458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide gel + violet LED
Description: Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by violet LED
Study NCT06165458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide gel + blue LED
Description: Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by blue LED
Study NCT05049083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Process SHR2554 tablet、Former Process SHR2554 tablet
Description: New Process, 350 mg SHR2554 tablets on study day 1 - Former Process, 350 mg SHR2554 tablets on study day 8
Study NCT05049083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Former Process SHR2554 tablet、New Process SHR2554 tablet
Description: Former Process, 350 mg SHR2554 tablets on study day 1 - New Process, 350 mg SHR2554 tablets on study day 8
Study NCT04760184 — intervention group
Intervention type: OTHER
Intervention: Autologous stem cell transplantation
Description: The study will describe the implications of COVID-19 infection following autologous stem cell transplantation
Study NCT04684654 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986325
Description: Specified dose on specified days
Study NCT05128422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy
Description: it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours.This therapy should begin in the emergency room as early as possible when patients meet the inclusion criteria and are randomized to the experimental group
Study NCT04684654 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-986325
Description: Specified dose on specified days
Study NCT04730895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral 13 cis retinoic acid
Description: Dose of 0.5 mg/kg/day in 2 divided doses orally for 14 days
Study NCT04730895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized 13 cis retinoic acid
Description: Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day
Study NCT04730895 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 13 cis retinoic acid doses orally in combination with spike protein based vaccine
Description: Dose of 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
Study NCT04730895 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine
Description: Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
Study NCT04730895 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine
Description: Dose of 5-7.5x10\^10vp of spike protein based vaccine such as ChAdOx1 nCoV-19 in deltoid of non-dominant arm, 28 days apart
Study NCT05823142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CB Sleep
Description: The CB-sleep intervention is a cognitive behavioral intervention guided by principles and practices from motivational interviewing and the psychology of behavior change, primarily drawing on self-efficacy and action planning theory. The goals of CB-sleep are for participants to achieve adequate sleep duration (7-9 hours per night), adequate sleep efficiency (≥ 85%), and regular sleep timing (\<60-minute differences in bed and wake times). The intervention components include improving sleep knowledge (hygiene), developing a nightly routine, addressing competing activities, modifying environmental conditions, lifestyle (avoiding caffeine and vigorous exercise before bed), technology (limiting or avoiding screens for at least one hour before bed), basic stress-management (progressive muscle relaxation and guided imagery), and self- monitoring.
Study NCT05152381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT05069701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SVV test
Description: SVV test will be done with virtual reality glasses.
Study NCT05426200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Patients will work with a health coach by telephone for up to 12 sessions over a 12-16 week period.
Study NCT05962008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHAPS® product
Description: Take 4 capsules per day after breakfast with warm water.
Study NCT05962008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BioPS® product
Description: Take 4 capsules per day after breakfast with warm water.
Study NCT05962008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 4 capsules per day after breakfast with warm water.
Study NCT04820751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine Hydrochloride 4 MG
Description: Cyproheptadine associated to standard care
Study NCT05239689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD38 CAR T-cells
Description: Drug: CD38 CAR T-cells Each subject receive CD38 CAR T-cells by intravenous infusion Other Name: CD38 CAR T-cells injection
Study NCT05369806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive two-way SMS dialogue
Description: This study uses Mobile WACh, a human-computer hybrid system that enables two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day. Women who experience pregnancy or infant loss will be enrolled into an infant loss track. The NLP model will be applied to incoming participant messages. Those flagged as urgent by the model will be flagged within the SMS system, allowing study nurses to triage and appropriately respond to those messages.
Study NCT04868630 — intervention group
Intervention type: DEVICE
Intervention: Pulsewave Health Monitor (PAD-2A) Device
Description: This is an observational study of the average breathing rate measurement of a non-invasive wrist cuff device. The purpose of this study is to calibrate the average breathing rate measurement of the Pulsewave Health Monitor (PAD-2A) wrist cuff device with the breathing rate measurement of a standard clinical capnography device. Additionally, we will also compare the average breathing rate measurement of the capnography device with other standard clinical respiratory devices (i.e. nasal pressure transducer, thermistor, and respiratory inductance plethysmography (RIP) belts of the chest and abdomen).
Study NCT04950868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
Study NCT06331091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Home exercise are done at home without the supervision of a specialist.
Study NCT06331091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Home exercise are done at home without the supervision of a specialist.